KRYS - NASDAQ
Krystal Biotech, Inc.
$301.82
+0.74%Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
At a Glance
Live SnapshotKrystal Biotech, Inc. Management Team
Ms. Kathryn A. Romano CPA
Executive Vice President & Chief Accounting Officer
Compensation
$661,467
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, Chairman, President & Chief Executive Officer
Compensation
$1,650,027
Ms. Suma M. Krishnan
Founder, President of R&D and Director
Compensation
$1,067,667
Mr. John Thomas
General Counsel & Corporate Secretary
Ms. Christine Wilson
Head of U.S. Sales & Marketing
Mr. Josh Suskin
Senior Director & Head of US Human Resources
Mr. Laurent Goux
Senior Vice President & GM of Europe
Dr. David Chien M.D.
Senior Vice President of Clinical Development
Mr. David Chien
Senior Vice President of Clinical Development
Dr. Stephane Paquette Ph.D.
Vice President of Corporate Development
Mr. John Karakkal
Vice President of North American Sales & Marketing
Krystal Biotech, Inc. Insider Positioning
During the last 12 months, insiders have sold $6.86M worth of KRYS shares, with no buying activity reported.
3 Months
0
0.00
642
193.90K
-194K
-$194K
3-6 Months
0
0.00
20.8K
5.57M
-5.6M
-$5.57M
6-9 Months
0
0.00
956
204.85K
-205K
-$205K
9-12 Months
0
0.00
5.9K
882.65K
-883K
-$883K
Top Buyers
No buying activity
Top Sellers
Janney Daniel
Director
$2.61M
Rossi Dino A
Director
$2.11M
Krishnan Suma
Director, 10 Percent Owner, Officer: President, R&D
$751K
Romano Kathryn
Officer: Chief Accounting Officer
$742K
Krishnan Krish S
Director, 10 Percent Owner, Officer: President And Ceo
$441K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.86M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
KRYS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | April 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 03, 2025 | April 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 04, 2024 | April 04, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 04, 2023 | April 04, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 20, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 06, 2021 | May 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 13, 2020 | May 29, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 15, 2019 | May 30, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 20, 2018 | May 31, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.